Quantum Surgical’s Epione® Robot Receives FDA Clearance for Abdominal Cancers

Quantum Surgical receives an extension of authorization from the US Food and Drug Administration (FDA) for its Epione^® robot, which can now treat abdominal cancers. Over four million patients could benefit from Epione^® treatment worldwide [1].

Quantum Surgical’s flagship product, the Epione^® robotic platform is dedicated to the curative treatment of cancers. Epione^® allows physicians to treat tumors that are particularly difficult to reach, due to their size or their location, at an early stage, in a simple and effective way.

Available in Europe and the United States, the Epione^® robot has already been used to treat more than 150 patients with liver or kidney cancer.

The extension of the Food and Drug Administration (FDA) authorization allows the commercial sale and use of the Epione^® robot in the United States to treat cancers of the entire abdomen. The abdomen is the space between the thorax and the pelvis, and includes in particular the following organs: liver, kidneys and adrenal glands, pancreas.

“We are very pleased to receive the FDA clearance. This decision allows physicians to now treat all abdominal tumors at an early stage and will accelerate the implementation of our innovative Epione^® robotics solution in the United States. And ultimately, enable more patients to benefit from innovative and less invasive treatments” says Bertin Nahum, president and co-founder of Quantum Surgical.

This authorization is supported by clinical data from the Gustave Roussy Cancer Center.

Source: Quantum Surgical